Vicarious Surgical

Vicarious Surgical

Vicarious Surgical was founded in 2014 by Adam Sachs and Sam Khalifa, who met at MIT and sought to reimagine surgical robotics from the inside out. The company’s core technology uses a bimanual, humanoid-style robot that enters the abdomen through a single 1.5-centimeter incision, potentially reducing trauma versus multi-port systems like Intuitive Surgical’s da Vinci. The firm raised approximately $100M in venture funding from investors including Bill Gates, Vinod Khosla, and Innovation Endeavors before going public. The company's strategy centers on developing a data-driven surgical ecosystem, with the robot capturing high-definition 3D video and sensor data during procedures — which could enable AI-assisted analytics and training. Vicarious Surgical targets general surgery procedures such as cholecystectomy and hernia repair, with plans to expand into gynecologic and colorectal applications. Its geographic focus is exclusively U.S. market clearance initially, with no disclosed international deployment strategy as of early 2025. Vicarious Surgical went public in October 2021 via a merger with a SPAC, D8 Holdings Corp., at an enterprise value of $1.3B. As of early 2025, the firm employs roughly 150 people and has not disclosed total deployment or AUM. A recent operational event: in March 2025, the company reported progress toward FDA 510(k) clearance for its surgical robot, citing completion of a pivotal clinical study (per the company's SEC filings, March 2025). No philanthropic or adjacent vehicles have been publicly identified. The company's structural differentiator is its single-incision bimanual architecture, which aims to combine the articulation of traditional laparoscopic tools with the ergonomics of a humanoid robot — a design that could reduce surgical footprint and OR setup time. However, Vicarious Surgical faces the challenge of displacing Intuitive's dominant installed base, which has over 9,000 da Vinci systems globally. Its path to commercial adoption hinges on demonstrating clinical equivalence or superiority in safety and outcomes versus established robotic surgery platforms.